SK72195A3 - Oxalylamino-benzofuran and benzothiene derivatives, method of their preparation, pharmaceutical agent containing these compounds and its use - Google Patents

Oxalylamino-benzofuran and benzothiene derivatives, method of their preparation, pharmaceutical agent containing these compounds and its use Download PDF

Info

Publication number
SK72195A3
SK72195A3 SK721-95A SK72195A SK72195A3 SK 72195 A3 SK72195 A3 SK 72195A3 SK 72195 A SK72195 A SK 72195A SK 72195 A3 SK72195 A3 SK 72195A3
Authority
SK
Slovakia
Prior art keywords
group
straight
carbon atoms
branched chain
same
Prior art date
Application number
SK721-95A
Other languages
English (en)
Slovak (sk)
Inventor
Gabriele Braunlich
Rudiger Fischer
Mazen Es-Sayed
Rudolf Hanko
Stephen Tudhope
Graham Sturton
Trevor Abram
Wendy J Mcdonald-Gibson
Mary F Fitzgerald
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410891A external-priority patent/GB9410891D0/en
Priority claimed from GB9410863A external-priority patent/GB9410863D0/en
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SK72195A3 publication Critical patent/SK72195A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Manufacturing Optical Record Carriers (AREA)
  • Medicinal Preparation (AREA)
SK721-95A 1994-05-31 1995-05-30 Oxalylamino-benzofuran and benzothiene derivatives, method of their preparation, pharmaceutical agent containing these compounds and its use SK72195A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410891A GB9410891D0 (en) 1994-05-31 1994-05-31 Oxalylamino-benzofuran-and benzothienyl-derivatives
GB9410863A GB9410863D0 (en) 1994-05-31 1994-05-31 Heterocyclycarbonyl substituted oxalylamino-benzofurane derivatives

Publications (1)

Publication Number Publication Date
SK72195A3 true SK72195A3 (en) 1995-12-06

Family

ID=26304969

Family Applications (1)

Application Number Title Priority Date Filing Date
SK721-95A SK72195A3 (en) 1994-05-31 1995-05-30 Oxalylamino-benzofuran and benzothiene derivatives, method of their preparation, pharmaceutical agent containing these compounds and its use

Country Status (29)

Country Link
US (1) US5565488A (fr)
EP (1) EP0685474B1 (fr)
JP (1) JPH083154A (fr)
KR (1) KR950032163A (fr)
CN (1) CN1119187A (fr)
AT (1) ATE171172T1 (fr)
AU (1) AU695464B2 (fr)
BG (1) BG99680A (fr)
CA (1) CA2150301A1 (fr)
CO (1) CO4600675A1 (fr)
CZ (1) CZ140895A3 (fr)
DE (1) DE69504753T2 (fr)
DK (1) DK0685474T3 (fr)
EE (1) EE9500034A (fr)
ES (1) ES2124461T3 (fr)
FI (1) FI952612A (fr)
HR (1) HRP950288A2 (fr)
HU (1) HUT71597A (fr)
IL (1) IL113894A (fr)
LV (1) LV11467B (fr)
MA (1) MA23603A1 (fr)
MY (1) MY130580A (fr)
NO (1) NO952129L (fr)
NZ (1) NZ272217A (fr)
PL (1) PL308825A1 (fr)
RO (1) RO113642B1 (fr)
SK (1) SK72195A3 (fr)
TN (1) TNSN95061A1 (fr)
ZA (1) ZA954400B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
CA2715683A1 (fr) 1999-08-21 2001-03-01 Nycomed Gmbh Combinaison synergiste
US7144885B2 (en) * 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
DE60307998T2 (de) * 2002-02-22 2007-04-05 Bayer Pharmaceuticals Corp., West Haven Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
US20040259926A1 (en) * 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
EP1644360A1 (fr) * 2003-06-05 2006-04-12 Warner-Lambert Company LLC Indoles 3-substitues et leurs derives utilises comme agents therapeutiques
CA2527793A1 (fr) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc Benzo[b]thiophenes substitues par 3-arylsulfanyle and 3-heteroarylsulfanyle utiles comme agents therapeutiques
CA2527341A1 (fr) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc Benzo[b]thiophenes cycloalkylsulfanyl substitues a titre d'agents therapeutiques
MXPA05012894A (es) * 2003-06-05 2006-02-22 Warner Lambert Co Benzofuranos 3-sustituidos como agentes terapeuticos.
EP1636210A1 (fr) * 2003-06-05 2006-03-22 Warner-Lambert Company LLC Benzothiophenes substitutes par cycloalkyle et heterocycloalkyle, utiles comme agents therapeutiques
CA2537119A1 (fr) * 2003-09-02 2005-03-10 Merck & Co., Inc. Compositions ophtalmiques pour le traitement de l'hypertension oculaire
WO2008025509A1 (fr) * 2006-09-01 2008-03-06 Bayer Schering Pharma Aktiengesellschaft Dérivés de benzofurane et de benzothiophène utiles dans le traitement de cancers du système nerveux central
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2744987C (fr) 2008-12-02 2018-01-16 Chiralgen, Ltd. Procede pour la synthese d'acides nucleiques modifies par des atomes de phosphore
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012039448A1 (fr) 2010-09-24 2012-03-29 株式会社キラルジェン Groupe auxiliaire asymétrique
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146243A1 (fr) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Inhibiteurs de la lipoxygénase
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives

Also Published As

Publication number Publication date
NO952129D0 (no) 1995-05-30
CA2150301A1 (fr) 1995-12-01
HU9501569D0 (en) 1995-07-28
ATE171172T1 (de) 1998-10-15
TNSN95061A1 (fr) 1996-02-06
IL113894A (en) 1999-06-20
HRP950288A2 (en) 1997-08-31
FI952612A0 (fi) 1995-05-29
LV11467A (lv) 1996-08-20
JPH083154A (ja) 1996-01-09
DE69504753D1 (de) 1998-10-22
LV11467B (en) 1996-12-20
NO952129L (no) 1995-12-01
BG99680A (en) 1996-01-31
RO113642B1 (ro) 1998-09-30
CZ140895A3 (en) 1995-12-13
US5565488A (en) 1996-10-15
NZ272217A (en) 1997-02-24
KR950032163A (ko) 1995-12-20
EP0685474A1 (fr) 1995-12-06
CN1119187A (zh) 1996-03-27
HUT71597A (en) 1996-01-29
MY130580A (en) 2007-06-29
MA23603A1 (fr) 1996-04-01
AU695464B2 (en) 1998-08-13
AU2028695A (en) 1995-12-07
CO4600675A1 (es) 1998-05-08
FI952612A (fi) 1995-12-01
DK0685474T3 (da) 1999-06-14
EE9500034A (et) 1995-12-15
ES2124461T3 (es) 1999-02-01
ZA954400B (en) 1996-01-24
EP0685474B1 (fr) 1998-09-16
DE69504753T2 (de) 1999-02-04
IL113894A0 (en) 1995-08-31
PL308825A1 (en) 1995-12-11

Similar Documents

Publication Publication Date Title
SK72195A3 (en) Oxalylamino-benzofuran and benzothiene derivatives, method of their preparation, pharmaceutical agent containing these compounds and its use
JP6215890B2 (ja) 縮合環類似体の抗線維症剤
EP0685475B1 (fr) Dérivés de aminobenzofuryle et -thienyle
CZ285799B6 (cs) Indolové deriváty, způsob jejich výroby, jejich použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem
US20110301160A1 (en) Inhibitors of P38 and Methods of Using the Same
SK53194A3 (en) Benzofuranyl and benzothiophenyl-alkanecarboxylic acid derivatives, method of their preparation and their using as medicaments
US20060058361A1 (en) Therapeutic diphenyl ether ligands
JPH07330763A (ja) ヘテロシクリルカルボニル置換されたベンゼンフラニル−および−チオフエニル−アルカンカルボン酸誘導体
CZ66796A3 (en) N-(3-benzofuranyl) urea derivatives, process of their preparation, preparations in which said derivatives are comprised and the use of the derivatives
US6670373B1 (en) Compounds and method for inhibiting MRP1
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
MXPA02009250A (es) 4-hidroxi-1,8-naftiridin--3-carboxamidas como agentes antivirales.
EP3077369B1 (fr) Dérivés de benzamide utiles dans le traitement des troubles et de la douleur musculaire(s) et pour le contrôle de la spasticité et des tremblements
US6458788B1 (en) 4-hydroxycinnoline-3-carboxyamides as antiviral agents
JP6943239B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
WO2023043024A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la fibrose interstitielle et de l'atrophie tubulaire en tant qu'antagoniste fonctionnel pour s1pr1 et s1pr4
WO2023042996A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la glomérulosclérose segmentaire focale agissant en tant qu'antagoniste fonctionnel pour s1pr1 et s1pr4
SK62293A3 (en) Substituted (benzothiazolyl and quinaxalyl-methoxy) phenyl-acetic acid derivatives
CA3227736A1 (fr) Composes n-acylhydrazoniques inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procedes d'obtention, compositions, utilisations, methodes de traitement et trousses
JPH04288077A (ja) チアゾール誘導体およびその製造法
JPH04210970A (ja) ベンズアミド誘導体及びその中間体